Mohs micrographic surgery (MMS) for atypical fibroxanthoma (AFX)—a fibrohistiocytic tumor with relatively high local recurrence rates, but low metastatic potential—is associated with a lower recurrence rate than wide local excision (WLE), a recent study found. Researchers sought to systematically review evidence of AFX recurrence and metastatic rates following different surgical modalities. They conducted a comprehensive literature search from 1946, or database inception, to March 20, 2017. 23 studies were selected (907 patients and 914 tumors). 175 cases were treated with MMS (recurrence rate, 2.0%; metastatic rate, 1.9%). 732 were treated with WLE (recurrence rate, 8.7; metastasis rate, 1%). Researchers found that among immunocompromised patients, no recurrence or metastases developed in the MMS subgroup, whereas 4 out of 10 recurred and 1 out of 10 metastasized in the WLE subgroup.
Tolkachjov SN, Kelley BF, Alahdab F, Erwin PJ, Brewer JD. Atypical fibroxanthoma: Systematic review and meta-analysis of treatment with Mohs micrographic surgery or excision. [Published online ahead of print July 5, 2018]. J Am Acad Dermatol. doi:10.1016/j.jaad.2018.06.048.
Must Reads in Dermatologic Surgery
Lymph Node Ratio and Survival Post-MCC Surgery, JAMA Dermatol; ePub 2019 Mar 2; Cheraghlou, et al
Nonsterile Gloves Safe for Skin Cancer Excisions, J Cosmet Dermatol; ePub 2019 Jan 20; Michener, et al